DoD Peer Reviewed Alzheimer’s Transforming Diagnosis Award
ID: 353148Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353148
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Peer Reviewed Alzheimer’s Transforming Diagnosis Award (TrDA) to enhance the diagnosis and prognosis of Alzheimer’s disease and related dementias. This grant aims to address significant barriers to diagnosis, such as technological limitations and equitable patient access, by requiring projects to demonstrate a clear pathway to clinical applicability, incorporate preliminary data, and engage community collaboration throughout the research process. With an estimated total program funding of $4 million and the potential for up to two awards of $2 million each over a maximum of four years, applicants must submit a two-step application consisting of a pre-application and a full application by the deadline of June 20, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524PRARPTrDA_v2.pdf
    The Department of Defense is offering a funding opportunity for the FY24 Peer Reviewed Alzheimer’s Transforming Diagnosis Award aimed at transforming diagnosis and prognosis for Alzheimer’s disease and related dementias. With a total appropriation of $15 million for FY24, proposals must prioritize addressing existing barriers to diagnosis, including technological limitations and equitable patient access. A clear pathway to clinical applicability, person-focused research, and community collaboration are key requirements. Applicants must engage communities in the research design and execution, ensuring that outcomes benefit diverse populations, particularly women and those affected by military health issues. The submission process includes a two-step application, consisting of a pre-application and a full application, with strict deadlines. Projects may seek up to $2 million over a maximum of four years and must incorporate preliminary data and community input into their strategies. The review process involves both peer evaluation for scientific merit and programmatic review for relevance, ensuring that awarded projects align with the goals of enhancing healthcare outcomes for affected individuals and communities.
    HT942524PRARPTrDA.pdf
    Similar Opportunities
    Alzheimer’s Research Program Transforming Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Research Award to support innovative research aimed at reducing the risk of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages diverse applicants, including for-profit, non-profit, and academic institutions, and emphasizes the necessity of community collaboration, particularly for clinical research projects. With an estimated total program funding of $4 million, the program anticipates awarding approximately four grants, each providing up to $1 million over a maximum of three years. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Care Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Care Award to support innovative clinical research aimed at improving care for individuals with Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity encourages community collaboration and requires projects to focus on interventions that enhance the quality of life for both patients and their caregivers. Approximately $5.2 million is available to fund around three awards, with pre-applications due by June 12, 2025, and full applications due by August 29, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Technology/Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (TTDA) to support the translation of promising preclinical findings into clinical applications for military personnel, veterans, and their families. This grant aims to facilitate the development of products that address military-related health challenges, including prevention, detection, diagnosis, treatment, or quality of life improvements, with a focus on innovative approaches in areas such as autoimmune disorders and infectious diseases. With an estimated total program funding of approximately $41.25 million available for up to 11 awards, applicants must submit a two-step application process, including a pre-application and a full application, by the closing date of July 21, 2025. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) to support innovative research aimed at developing therapies for Amyotrophic Lateral Sclerosis (ALS). This grant program seeks applications that demonstrate proof-of-concept efficacy in preclinical models of ALS, with a focus on empirical therapeutic studies and the development of mechanism-specific biomarkers to enhance trial design and patient selection. With an estimated total funding of approximately $9.8 million, the program anticipates awarding about four grants, each capped at $1.5 million for a maximum duration of three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity under the Peer Reviewed Medical Research Program (PRMRP) for the fiscal year 2025, specifically for the Clinical Trial Award (CTA). This program aims to support the rapid implementation of clinical trials that can significantly impact the treatment or management of diseases relevant to military health, with a focus on areas such as autoimmune disorders, cardiovascular health, infectious diseases, and neuroscience. Approximately $32 million is available for this initiative, with an expected four awards, each capped at $8 million, and applications are due by July 21, 2025. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. This funding initiative aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly focusing on therapies effective across all age groups, including infants and nonambulatory individuals. With an estimated total program funding of approximately $8.56 million, the program anticipates awarding around five grants, encouraging collaborations with early-career investigators and requiring applications to include preliminary data relevant to DMD. Interested applicants should note that a pre-application is due by July 25, 2025, with full applications due by August 8, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Therapeutic Idea Award (TIA) under the fiscal year 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP). This grant aims to support innovative, high-risk research proposals focused on drug or therapy development for Amyotrophic Lateral Sclerosis (ALS), with an emphasis on generating preliminary data for future therapeutic investigations. The program has a total funding amount of approximately $10.8 million, with individual awards capped at $600,000 and a performance period not exceeding two years. Interested applicants must submit pre-applications by June 6, 2025, and full applications by August 27, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award to support clinical trials aimed at improving the treatment and management of Amyotrophic Lateral Sclerosis (ALS). Applicants are required to focus on either biomarker-driven interventions or enhancements in clinical care, with an emphasis on incorporating community collaboration to optimize research impact. This funding opportunity allocates approximately $6.6 million to support around two pilot clinical trial applications, with a direct cost cap of $2 million for each project. Interested parties must submit a pre-application by June 6, 2025, followed by a full application due on August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This grant aims to support the development and validation of clinical outcomes and biomarkers specifically for enhancing clinical trials in Amyotrophic Lateral Sclerosis (ALS), focusing on targeted therapies or genetic mutations rather than broad applicability to all patients. With an estimated total program funding of $6.2 million, the program anticipates awarding approximately five grants, each with a maximum budget of $750,000 for a duration of up to three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Duchenne Muscular Dystrophy, Idea Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is offering the Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) for fiscal year 2025. This grant aims to support innovative, high-risk research that seeks to improve outcomes for individuals with Duchenne muscular dystrophy (DMD), encouraging applications that present well-formulated hypotheses based on solid scientific rationale. The program is particularly focused on studies targeting the primary pathology of DMD and emphasizes collaboration among experienced researchers, while excluding clinical trials in favor of fundamental and preparatory research. The total funding available is approximately $1.68 million, with up to three awards capped at $350,000 each for direct costs over a maximum of two years. Interested applicants must submit a pre-application by July 2025, followed by a full application by August 2025, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.